Published in Infect Immun on September 01, 1999
Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol (2001) 7.97
Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. PLoS One (2014) 4.94
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun (1999) 2.94
Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun (2000) 2.84
Streptococcus adherence and colonization. Microbiol Mol Biol Rev (2009) 2.83
Role of novel choline binding proteins in virulence of Streptococcus pneumoniae. Infect Immun (2000) 2.75
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A (2002) 2.72
Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun (2000) 2.64
Microarray analysis of pneumococcal gene expression during invasive disease. Infect Immun (2004) 2.38
Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun (2002) 2.15
The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun (2009) 2.09
PspC, a pneumococcal surface protein, binds human factor H. Infect Immun (2001) 1.92
Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun (2004) 1.91
Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection. Infect Immun (2001) 1.81
Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun (2006) 1.80
Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun (2003) 1.70
Generation of genic diversity among Streptococcus pneumoniae strains via horizontal gene transfer during a chronic polyclonal pediatric infection. PLoS Pathog (2010) 1.66
Regulation of the pspA virulence factor and essential pcsB murein biosynthetic genes by the phosphorylated VicR (YycF) response regulator in Streptococcus pneumoniae. J Bacteriol (2005) 1.63
Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun (2001) 1.62
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood (2008) 1.55
PavA of Streptococcus pneumoniae modulates adherence, invasion, and meningeal inflammation. Infect Immun (2005) 1.54
Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun (2003) 1.54
PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun (2004) 1.53
Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect Immun (2008) 1.42
Characterization of binding of human lactoferrin to pneumococcal surface protein A. Infect Immun (2001) 1.40
Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun (2008) 1.33
Differential protein expression in phenotypic variants of Streptococcus pneumoniae. Infect Immun (2000) 1.32
Extracellular gelatinase of Enterococcus faecalis destroys a defense system in insect hemolymph and human serum. Infect Immun (2007) 1.28
The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses. Infect Immun (2000) 1.28
Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model. Infect Immun (2007) 1.25
Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun (2007) 1.23
Contribution of choline-binding proteins to cell surface properties of Streptococcus pneumoniae. Infect Immun (2002) 1.23
Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. Infect Immun (2005) 1.22
PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation. Infect Immun (2007) 1.17
Innate immune defense against pneumococcal pneumonia requires pulmonary complement component C3. Infect Immun (2005) 1.14
The human complement regulator factor H binds pneumococcal surface protein PspC via short consensus repeats 13 to 15. Infect Immun (2002) 1.14
Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog (2007) 1.13
Multifunctional role of choline binding protein G in pneumococcal pathogenesis. Infect Immun (2006) 1.11
The effects of PspC on complement-mediated immunity to Streptococcus pneumoniae vary with strain background and capsular serotype. Infect Immun (2009) 1.11
Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect Immun (2003) 1.09
Role of complement in host defense against pneumococcal otitis media. Infect Immun (2009) 1.09
PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun (2009) 1.09
Species-specific interaction of Streptococcus pneumoniae with human complement factor H. J Immunol (2008) 1.08
Animal models of Streptococcus pneumoniae disease. Clin Microbiol Rev (2008) 1.07
Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol (2010) 1.06
PspK of Streptococcus pneumoniae increases adherence to epithelial cells and enhances nasopharyngeal colonization. Infect Immun (2012) 1.06
The capsular serotype of Streptococcus pneumoniae is more important than the genetic background for resistance to complement. Infect Immun (2010) 1.05
Interaction of pneumococcal histidine triad proteins with human complement. Infect Immun (2010) 1.05
Cirrhosis-induced defects in innate pulmonary defenses against Streptococcus pneumoniae. BMC Microbiol (2007) 1.04
The contribution of PspC to pneumococcal virulence varies between strains and is accomplished by both complement evasion and complement-independent mechanisms. Infect Immun (2006) 1.03
Two DHH subfamily 1 proteins contribute to pneumococcal virulence and confer protection against pneumococcal disease. Infect Immun (2011) 1.02
Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol (2012) 1.01
Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage. Infect Immun (2005) 1.00
Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b. Infect Immun (2012) 0.98
Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One (2010) 0.98
Pneumococci: immunology of the innate host response. Respirology (2010) 0.95
Borrelia burgdorferi binding of host complement regulator factor H is not required for efficient mammalian infection. Infect Immun (2007) 0.95
The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin Vaccine Immunol (2012) 0.95
Expansion and evolution of the Streptococcus pneumoniae Spain9V-ST156 clonal complex in Poland. Antimicrob Agents Chemother (2010) 0.94
Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence. Infect Immun (2010) 0.94
Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Infect Immun (2002) 0.94
Serotype-related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniae. Infect Immun (2010) 0.93
Expression of cytokine and chemokine genes by human middle ear epithelial cells induced by influenza A virus and Streptococcus pneumoniae opacity variants. Infect Immun (2003) 0.91
Pneumococci in biofilms are non-invasive: implications on nasopharyngeal colonization. Front Cell Infect Microbiol (2014) 0.90
Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniae. Clin Vaccine Immunol (2008) 0.89
Protective activity of Streptococcus pneumoniae Spr1875 protein fragments identified using a phage displayed genomic library. PLoS One (2012) 0.89
Biofilm and planktonic pneumococci demonstrate disparate immunoreactivity to human convalescent sera. BMC Microbiol (2011) 0.88
Binding of Streptococcus pneumoniae endopeptidase O (PepO) to complement component C1q modulates the complement attack and promotes host cell adherence. J Biol Chem (2014) 0.88
Differential role of CbpA and PspA in modulation of in vitro CXC chemokine responses of respiratory epithelial cells to infection with Streptococcus pneumoniae. Infect Immun (2006) 0.87
Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives. PLoS One (2013) 0.85
Essential role of factor B of the alternative complement pathway in complement activation and opsonophagocytosis during acute pneumococcal otitis media in mice. Infect Immun (2011) 0.85
The pneumococcal two-component signal transduction system RR/HK06 regulates CbpA and PspA by two distinct mechanisms. J Bacteriol (2007) 0.85
Host stress hormone norepinephrine stimulates pneumococcal growth, biofilm formation and virulence gene expression. BMC Microbiol (2014) 0.85
Effects of Streptococcus pneumoniae strain background on complement resistance. PLoS One (2011) 0.83
Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response. Clin Vaccine Immunol (2013) 0.83
Contribution of different pneumococcal virulence factors to experimental meningitis in mice. BMC Infect Dis (2013) 0.82
Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion. Infect Immun (2016) 0.82
Monitoring the long-term molecular epidemiology of the pneumococcus and detection of potential 'vaccine escape' strains. PLoS One (2011) 0.81
Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infections. Bioeng Bugs (2011) 0.80
Pneumococcal phosphorylcholine esterase, Pce, contains a metal binuclear center that is essential for substrate binding and catalysis. Protein Sci (2005) 0.80
Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection. Clin Vaccine Immunol (2015) 0.80
Choline Binding Proteins from Streptococcus pneumoniae: A Dual Role as Enzybiotics and Targets for the Design of New Antimicrobials. Antibiotics (Basel) (2016) 0.79
Evolution and genetic diversity of the Spain23F-ST81 clone causing adult invasive pneumococcal disease in Barcelona (1990-2012). J Antimicrob Chemother (2013) 0.79
Highly Variable Streptococcus oralis Strains Are Common among Viridans Streptococci Isolated from Primates. mSphere (2016) 0.79
Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A. Clin Vaccine Immunol (2013) 0.78
C-Terminal Clostridium perfringens Enterotoxin-Mediated Antigen Delivery for Nasal Pneumococcal Vaccine. PLoS One (2015) 0.78
Effect of apolactoferrin on experimental pneumococcal otitis media. Arch Otolaryngol Head Neck Surg (2010) 0.78
Diverse evolutionary patterns of pneumococcal antigens identified by pangenome-wide immunological screening. Proc Natl Acad Sci U S A (2017) 0.76
Novel Strategy To Protect against Influenza Virus-Induced Pneumococcal Disease without Interfering with Commensal Colonization. Infect Immun (2016) 0.76
Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC. Clin Vaccine Immunol (2014) 0.76
A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia. J Infect Dis (2015) 0.75
Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against S. pneumoniae infection in mice. Ther Adv Vaccines (2017) 0.75
Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins. Clin Vaccine Immunol (2014) 0.75
The type II histidine triad protein HtpsC is a novel adhesion with the involvement of Streptococcus suis virulence. Virulence (2015) 0.75
Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity. Front Microbiol (2017) 0.75
Intradermal immunization of mice with cholera toxin B-pneumococcal surface protein A fusion protein is protective against intraperitoneal challenge with Streptococcus pneumoniae. Infect Immun (2005) 0.75
Towards Identifying Protective B-Cell Epitopes: The PspA Story. Front Microbiol (2017) 0.75
A combination of recombinant BCG expressing pneumococcal proteins induces cellular and humoral immune responses and protects against pneumococcal colonization and sepsis. Clin Vaccine Immunol (2017) 0.75
Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med (1981) 6.45
Genetic control of the antibody response to type 3 pneumococcal polysaccharide in mice. I. Evidence that an X-linked gene plays a decisive role in determining responsiveness. J Exp Med (1972) 5.19
Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol (1997) 4.78
Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med (1987) 3.94
Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun (1990) 3.66
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol (1982) 3.23
Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med (1984) 3.02
SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol Microbiol (1997) 3.01
Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol (1992) 2.80
Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci U S A (1997) 2.44
Alternate complement pathway activation by group A streptococci: role of M-protein. Infect Immun (1979) 2.39
Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. J Biol Chem (1990) 2.13
Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev (1998) 2.06
Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis (1996) 1.97
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology (1999) 1.94
Analysis of C3 deposition and degradation on bacterial surfaces after opsonization. J Infect Dis (1988) 1.86
Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun (1989) 1.86
Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae. Rev Infect Dis (1988) 1.70
Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin production. Infect Immun (1997) 1.67
Activation of C3 via the alternative complement pathway results in fixation of C3b to the pneumococcal cell wall. J Immunol (1980) 1.54
Location of the complement factor H binding site on streptococcal M6 protein. Infect Immun (1995) 1.44
Resistance to phagocytosis by group A streptococci: failure of deposited complement opsonins to interact with cellular receptors. J Immunol (1985) 1.37
Pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep (1989) 1.24
Interaction of gram-positive microorganisms with complement. Curr Top Microbiol Immunol (1985) 1.19
Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection. J Pediatr (1994) 1.10
Solid phase enzyme immunoassays for the quantification of serum amyloid P (SAP) and complement component 3 (C3) proteins in acute-phase mouse sera. Horm Metab Res (1992) 1.02
Identification of the IgA-binding region in streptococcal protein Arp. J Immunol (1994) 0.96
Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med (1981) 6.45
Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun (1989) 5.23
Subclass restriction of murine anti-carbohydrate antibodies. J Immunol (1978) 4.99
Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med (1987) 3.94
Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun (1990) 3.66
Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis (1992) 3.52
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J Bacteriol (1992) 3.05
Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med (1984) 3.02
PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun (1991) 2.96
The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun (1999) 2.94
Transformation of encapsulated Streptococcus pneumoniae. J Bacteriol (1986) 2.82
Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol (1992) 2.80
Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med (1982) 2.79
Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun (2000) 2.64
Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int (2007) 2.64
Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis (1997) 2.50
Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathog (1997) 2.41
Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med (Berl) (2005) 2.29
Anti-DNA autoantibodies in (NZB X NZW)F1 mice are clonally heterogeneous, but the majority share a common idiotype. J Immunol (1982) 2.25
Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog (1994) 2.20
Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody. Infect Immun (1982) 2.19
Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature (1981) 2.16
Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis (2000) 2.11
Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine (2000) 2.07
A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice. Infect Immun (1995) 2.01
Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine (2000) 2.00
Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis (1996) 1.97
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology (1999) 1.94
IgG anti-DNA autoantibodies within an individual autoimmune mouse are the products of clonal selection. J Immunol (1989) 1.81
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J Immunol (1982) 1.77
The ability of Salmonella typhimurium to produce the siderophore enterobactin is not a virulence factor in mouse typhoid. Infect Immun (1985) 1.77
The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin. J Bacteriol (2001) 1.77
Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun (2001) 1.74
Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia. J Immunol (1984) 1.72
The primary effect of the Ity locus is on the rate of growth of Salmonella typhimurium that are relatively protected from killing. J Immunol (1990) 1.71
No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol (2005) 1.70
The IS1167 insertion sequence is a phylogenetically informative marker among isolates of serotype 6B Streptococcus pneumoniae. J Mol Evol (1998) 1.68
Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin production. Infect Immun (1997) 1.67
Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies. Microb Pathog (1986) 1.64
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol (1995) 1.61
Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun (1996) 1.60
Eating patterns and dietary composition in relation to BMI in younger and older adults. Int J Obes (Lond) (2006) 1.56
Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med (1994) 1.55
The hemolytic and complement-activating properties of pneumolysin do not contribute individually to virulence in a pneumococcal bacteremia model. Microb Pathog (1997) 1.55
Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae. Microb Pathog (1990) 1.53
Binge eating disorder in extreme obesity. Int J Obes Relat Metab Disord (2002) 1.53
Genetic control of the susceptibility to pneumococcal infection. Curr Top Microbiol Immunol (1986) 1.50
A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence. Infect Immun (1991) 1.48
Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. J Immunol (1984) 1.48
Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membrane. Microb Pathog (1992) 1.48
Epidemiological studies of Streptococcus pneumoniae in infants: development of antibody to phosphocholine. J Clin Microbiol (1983) 1.45
A 'safe-site' for Salmonella typhimurium is within splenic polymorphonuclear cells. Microb Pathog (1992) 1.44
Blood clearance of Streptococcus pneumoniae by C-reactive protein. J Immunol (1987) 1.42
Characterization of binding of human lactoferrin to pneumococcal surface protein A. Infect Immun (2001) 1.40
Molecular localization of variable and conserved regions of pspA and identification of additional pspA homologous sequences in Streptococcus pneumoniae. Microb Pathog (1992) 1.39
Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun (2002) 1.37
Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol (2000) 1.37
A 'safe-site' for Salmonella typhimurium is within splenic cells during the early phase of infection in mice. Microb Pathog (1991) 1.35
A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun (1998) 1.33
Psychological measures of eating behavior and the accuracy of 3 common dietary assessment methods in healthy postmenopausal women. Am J Clin Nutr (2000) 1.33
Evidence for separate genetic defects in C3H/HeJ and C3HeB/FeJ mice, that affect susceptibility to gram-negative infections. J Immunol (1985) 1.32
Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg Infect Dis (2001) 1.30
Phagocytosis and killing of salmonella typhimurium by peritoneal exudate cells. Infect Immun (1981) 1.29
Resistance to Streptococcus pneumoniae is induced by a phosphocholine-protein conjugate. J Immunol (1983) 1.27
Isoelectric focusing of immunoglobulins: improved methodology. J Immunol Methods (1980) 1.26
Protein serotyping of Streptococcus pneumoniae based on reactivity to six monoclonal antibodies. Microb Pathog (1988) 1.25
Clonal dominance. I. Restricted nature of the IgM antibody response to group A streptococcal carbohydrate in mice. J Exp Med (1975) 1.24
Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect Immun (1997) 1.24
Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun (2007) 1.23
Development of a multi-specificity opsonophagocytic killing assay. Vaccine (2000) 1.22
A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J Immunol (1998) 1.21
C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med (1999) 1.20
Salmonella typhimurium virulence genes necessary to exploit the Itys/s genotype of the mouse. Infect Immun (1986) 1.20
A protective monoclonal antibody that reacts with a novel antigen of pneumococcal teichoic acid. Microb Pathog (1987) 1.18
Clones of Streptococcus pneumoniae isolated from nasopharyngeal carriage and invasive disease in young children in central Tennessee. J Infect Dis (2001) 1.18
The Salmonella typhimurium locus mviA regulates virulence in Itys but not Ityr mice: functional mviA results in avirulence; mutant (nonfunctional) mviA results in virulence. J Exp Med (1991) 1.16
Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil (1995) 1.16
Detection of isoelectric focused antibody by autoradiography and hemolysis of antigen-coated erythrocytes. A comparison of methods. J Immunol Methods (1975) 1.16
Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun (1999) 1.15
Oligonucleotides identify conserved and variable regions of pspA and pspA-like sequences of Streptococcus pneumoniae. Gene (1997) 1.14
Hand-held dynamometry reliability in persons with neuropathic weakness. Arch Phys Med Rehabil (1997) 1.13
In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions. J Immunol (1999) 1.10
Immune response deficiency of BSVS mice. II. Generalized deficiency to thymus-dependent antigens. Eur J Immunol (1979) 1.10
Human antibodies to phosphocholine. IgG anti-PC antibodies express restricted numbers of V and C regions. J Immunol (1987) 1.10
Complement C3 activation in cyst fluid and urine from autosomal dominant polycystic kidney disease patients. J Intern Med (2014) 1.07
Circulating parasite antigen(s) in lymphatic filariasis: use of monoclonal antibodies to phosphocholine for immunodiagnosis. J Immunol (1987) 1.07
Complete sharing of light chain spectrotypes by murine IgM and IgG anti-streptococcal antibodies. J Immunol (1977) 1.05
Analysis of the diversity of murine antibodies to dextran B1355. III. Idiotypic and spectrotypic correlations. Eur J Immunol (1978) 1.05
Streptococcal group A carbohydrate has properties of both a thymus-independent (TI-2) and a thymus-dependent antigen. J Immunol (1982) 1.04
A simple method for estimating the probable numbers of different antibodies by examining the repeat frequencies of sequences or isoelectric focusing patterns. Mol Immunol (1981) 1.04
A randomized study of the effects of aerobic exercise by lactating women on breast-milk volume and composition. N Engl J Med (1994) 1.03
Naturally occurring antibodies to phosphocholine as a potential index of antibody responsiveness to polysaccharides. J Infect Dis (1987) 1.03
Mouse strain-specific idiotypy and interstrain idiotypic cross-reactions. J Immunol (1974) 1.03
Food cravings and energy regulation: the characteristics of craved foods and their relationship with eating behaviors and weight change during 6 months of dietary energy restriction. Int J Obes (Lond) (2007) 1.03
Genetic mapping of novel virulence determinants of Salmonella typhimurium to the region between trpD and supD. Microb Pathog (1986) 1.02
Relative influence of diet and physical activity on cardiovascular risk factors in urban Chinese adults. Int J Obes Relat Metab Disord (2003) 1.01